Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

Bone Marrow Transplantation volume 37, pages 539–546 (2006)Cite this article

Abstract

Hematopoietic stem cell transplant (HSCT) recipients are at risk for Epstein–Barr virus (EBV)-associated, post transplant lymphoproliferative disorder (PTLD). Studies have suggested that early treatment may improve the outcome of patients with PTLD. Thus, significant attention has been focused on PCR-based approaches for preemptive (i.e., prior to clinical presentation) diagnosis. Reports from several transplant centers have demonstrated that HSCT recipients with PTLD generally have higher concentrations of EBV DNA in the peripheral blood than patients without PTLD. However, the PCR values of patients with PTLD typically span multiple orders of magnitude and overlap significantly with values from patients without PTLD. Thus, questions remain about the sensitivity and predictive value of these assays. Preemptive strategies using rituximab and/or EBV-specific cytotoxic T lymphocytes have been evaluated in patients with elevated EBV viral loads. We review the current literature, discuss our institutional experience and identify several areas of future research that could improve the diagnosis and treatment of this life-threatening disorder in HSCT recipients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Faye A, Vilmer E . Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 2005; 7: 55–65.

    Article  PubMed  Google Scholar 

  2. Gottschalk S, Rooney CM, Heslop HE . Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29–44.

    Article  CAS  PubMed  Google Scholar 

  3. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L . Biology and adoptive cell therapy of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195–216.

    Article  CAS  PubMed  Google Scholar 

  4. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.

    CAS  PubMed  Google Scholar 

  5. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–3661.

    CAS  PubMed  Google Scholar 

  6. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.

    CAS  PubMed  Google Scholar 

  7. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–233.

    Article  PubMed  Google Scholar 

  8. Hoshino Y, Kimura H, Tanaka N, Tsuge I, Kudo K, Horibe K et al. Prospective monitoring of the Epstein–Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001; 115: 105–111.

    Article  CAS  PubMed  Google Scholar 

  9. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–978.

    Article  CAS  PubMed  Google Scholar 

  10. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981.

    Article  CAS  PubMed  Google Scholar 

  11. Hale G, Waldmann H . Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood 1998; 91: 3079–3083.

    CAS  PubMed  Google Scholar 

  12. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–239.

    Article  PubMed  Google Scholar 

  13. Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J et al. Low incidence of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7: 395–399.

    Article  CAS  PubMed  Google Scholar 

  14. Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM . Role of Epstein–Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831–840.

    Article  PubMed  Google Scholar 

  15. Rowe DT, Webber S, Schauer EM, Reyes J, Green M . Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transplant Infect Dis 2001; 3: 79–87.

    Article  CAS  Google Scholar 

  16. Allen U, Hebert D, Petric M, Tellier R, Tran D, Superina R et al. Utility of semiquantitative polymerase chain reaction for Epstein–Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 2001; 33: 145–150.

    Article  CAS  PubMed  Google Scholar 

  17. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.

    CAS  PubMed  Google Scholar 

  18. Heslop HE, Rooney CM . Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157: 217–222.

    Article  CAS  PubMed  Google Scholar 

  19. Meerbach A, Gruhn B, Egerer R, Reischl U, Zintl F, Wutzler P . Semiquantitative PCR analysis of Epstein–Barr virus DNA in clinical samples of patients with EBV-associated diseases. J Med Virol 2001; 65: 348–357.

    Article  CAS  PubMed  Google Scholar 

  20. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J . Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543–558.

    Article  PubMed  Google Scholar 

  21. Beck R, Westdorp I, Jahn G, Schafer H, Kanz L, Einsele H . Detection of Epstein–Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol 1999; 37: 3430–3431.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Dominietto A, Tedone E, Soracco M, Bregante S, di Grazia C, Galbusera V et al. Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplant based on molecular monitoring is predictive of lymphoproliferative disease [Abstract]. Bone Marrow Transplant 2004; 33: S192.

    Google Scholar 

  23. Fontan J, Bassignot A, Mougin C, Cahn JY, Lab M . Detection of Epstein–Barr virus DNA in serum of transplanted patients: a new diagnostic guide for lymphoproliferative diseases. Leukemia 1998; 12: 772.

    Article  CAS  PubMed  Google Scholar 

  24. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Dilloo D et al. Evaluation of use of Epstein–Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351–358.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lankester AC, van Tol MJ, Vossen JM, Kroes AC, Claas E . Epstein–Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002; 99: 2630–2631.

    Article  CAS  PubMed  Google Scholar 

  26. Ohga S, Kubo E, Nomura A, Takada H, Suga N, Ishii E et al. Quantitative monitoring of circulating Epstein–Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. Int J Hematol 2001; 73: 323–326.

    Article  CAS  PubMed  Google Scholar 

  27. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE . Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.

    Article  CAS  PubMed  Google Scholar 

  28. Sirvent-von Bueltzingsloewen A, Morand P, Buisson M, Souillet G, Chambost H, Bosson JL et al. A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant 2002; 29: 21–28.

    Article  CAS  PubMed  Google Scholar 

  29. Stevens SJ, Pronk I, Middeldorp JM . Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211–1216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Biasolo MA, Calistri A, Cesaro S, Gentile G, Mengoli C, Palu G . Case report: kinetics of Epstein–Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. J Med Virol 2003; 69: 220–224.

    Article  PubMed  Google Scholar 

  31. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165–1171.

    Article  CAS  PubMed  Google Scholar 

  32. van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814–821.

    Article  CAS  PubMed  Google Scholar 

  33. Zia MI, Siu LL, Pond GR, Chen EX . Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005; 23: 6982–6991.

    Article  CAS  PubMed  Google Scholar 

  34. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD . Development of a real-time quantitative assay for detection of Epstein–Barr virus. J Clin Microbiol 2000; 38: 712–715.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–4369.

    Article  CAS  PubMed  Google Scholar 

  36. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–1505.

    CAS  PubMed  Google Scholar 

  37. Gruhn B, Meerbach A, Hafer R, Zell R, Wutzler P, Zintl F . Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1023–1025.

    Article  CAS  PubMed  Google Scholar 

  38. McGuirk JP, Seropian S, Howe G, Smith B, Stoddart L, Cooper DL . Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999; 24: 1253–1258.

    Article  CAS  PubMed  Google Scholar 

  39. Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E . High fatality rate of Epstein–Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005; 43: 3540–3543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555.

    CAS  PubMed  Google Scholar 

  41. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551–555.

    Article  CAS  PubMed  Google Scholar 

  42. Gratama JW, Cornelissen JJ . Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. BioDrugs 2003; 17: 325–338.

    Article  CAS  PubMed  Google Scholar 

  43. Marshall NA, Howe JG, Formica R, Krause D, Wagner JE, Berliner N et al. Rapid reconstitution of Epstein–Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96: 2814–2821.

    CAS  PubMed  Google Scholar 

  44. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N et al. Impaired recovery of Epstein–Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290–4297.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Division, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    D M Weinstock & A Jakubowski

  2. Division of Infectious Diseases, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    D M Weinstock

  3. The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    G G Ambrossi

  4. Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    C Brennan & T E Kiehn

Authors
  1. D M Weinstock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G G Ambrossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T E Kiehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Jakubowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D M Weinstock.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weinstock, D., Ambrossi, G., Brennan, C. et al. Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 37, 539–546 (2006). https://doi.org/10.1038/sj.bmt.1705289

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705289

Keywords

This article is cited by

Search

Advanced search

Quick links